Financial Toxicity Strikes Nearly Half of Sarcoma Patients, Largest US Study Reveals

A sweeping new study from Vanderbilt University Medical Center has delivered the clearest picture yet of a hidden burden carried by people battling one of medicine’s rarest and most demanding groups of cancers. Among 1,125 adult sarcoma patients who completed a validated financial distress questionnaire, close to half reported some degree of financial toxicity, the term researchers use to describe the measurable distress that arises when the cost of illness collides with a household’s ability to pay. The findings, published in Cancer Reports, represent the largest United States based investigation of financial toxicity in an unselected sarcoma population, spanning patients from young adults to the elderly, across every major sarcoma subtype, and at every stage of the treatment journey.

Financial toxicity is not simply a synonym for medical debt. It describes a clinical phenomenon with documented consequences: poorer quality of life, reduced adherence to treatment, missed follow up appointments, and even decreased survival. Until now, most of the evidence came from patients with far more common malignancies such as breast, prostate, lung, and colorectal cancers. Sarcoma patients, who number only a small fraction of cancer diagnoses, have been largely invisible in this literature, despite facing a treatment landscape that frequently combines surgery, chemotherapy, radiation, and targeted therapies, often with lasting physical and mobility impairments that erode earning potential while expenses mount.

The research team drew on the CAUSAL cohort, an informatics driven registry constructed from the Vanderbilt Sarcoma Center that enrolls patients of any age with confirmed sarcoma. Between April 2022 and August 2025, 1,499 adults enrolled, and 1,125 completed the COmprehensive Score for financial Toxicity, or COST, an eleven item instrument scored from 0 to 44 in which lower numbers signal greater distress. Participants rated their experience over the previous seven days on five point scales, and the researchers stratified results into severe, moderate, mild, and no financial toxicity using thresholds originally proposed by de Souza and colleagues. Clinical, insurance, and treatment data were abstracted from the electronic health record, while psychosocial and functional outcomes were captured with the PROMIS 57 profile, a standardized battery measuring anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and social participation.

The headline numbers were sobering. The median COST score across the cohort was 27.0, just above the threshold separating distress from financial stability. In total, 44.6 percent of participants reported at least mild financial toxicity, including 29.2 percent with mild, 15.1 percent with moderate, and 0.4 percent with severe distress. The burden was heavier among those still in active treatment: 48.9 percent of on therapy patients reported some level of financial toxicity, compared with 41 percent of those in post treatment surveillance. This prevalence sits within the broad 45 to 80 percent range reported for other malignancies, but the sarcoma figures carry particular weight because no prior US study had established a baseline for this population.

Multivariable linear regression, adjusted for demographics, disease characteristics, and treatment variables, revealed a consistent demographic signature. Each additional decade of age was associated with a 1.28 point increase in COST score, meaning older patients fared better, while every 10,000 dollar rise in household income added 0.87 points of financial protection. Male gender conferred a 1.93 point advantage. On the other side of the ledger, non White race was associated with a 1.77 point decrease, each additional household member with a 0.73 point decrease, metastatic disease with a 2.36 point decrease, and active treatment with a 1.61 point decrease, all signaling greater financial harm. All variance inflation factors remained below five, indicating the model was not distorted by collinearity among predictors.

The age effect deserves particular attention because it runs counter to simple intuition that older patients, living on fixed incomes, would be most vulnerable. Instead, the pattern mirrors findings across many cancer types: younger adults are consistently hit hardest. The authors point to the structure of sarcoma care as an explanation. Treatment is often prolonged and sometimes requires hospitalization, disrupting employment and education at precisely the life stage when people are building careers, savings, and insurance continuity. Younger patients have had less time to accumulate financial reserves or qualify for retirement benefits, and as survival improves, they face greater cumulative financial demands over longer post treatment lives.

Household composition emerged as a surprisingly potent and understudied factor. Among patients off therapy, each additional person supported by the household income was associated with a 0.79 point drop in COST score, an effect that persisted even after accounting for income itself. The interpretation is straightforward: income is a fixed resource, and every additional mouth to feed stretches it thinner. No prior US cohort, and no sarcoma specific study anywhere, had examined this relationship, making it one of the novel contributions of the analysis.

Perhaps the most clinically provocative findings concerned the mind body financial connection. Among the 832 participants who completed both the COST and all seven PROMIS 57 domains, every ten point increase in the standardized T score for anxiety was associated with a 0.77 point decrease in COST, depression with a 2.11 point decrease, pain interference with a 1.36 point decrease, and sleep disturbance with a 0.68 point decrease. In other words, worse psychological and physical symptoms tracked with greater financial distress. The direction of causality cannot be established from a cross sectional design, and the authors are careful on this point: financial toxicity may drive distress, baseline suffering may precipitate financial hardship, or the two may reinforce each other in a feedback loop. A Dutch study of gastrointestinal stromal tumor patients on tyrosine kinase inhibitors had previously linked anxiety to trouble paying expenses, and breast cancer research has tied financial stress to difficulty falling asleep, but no US study had examined these associations specifically in sarcoma.

The study has honest limitations that shape how the results should be read. It is a single center, cross sectional analysis, and the cohort is predominantly White, reflecting the demographics of the Tennessee Cancer Registry but limiting generalizability to more diverse populations. Participants who completed the full PROMIS battery were systematically more educated and more likely to have commercial insurance than those who completed only the COST measure, raising the possibility that the true prevalence of financial toxicity is underestimated. The researchers also lacked objective financial metrics such as out of pocket expenditures, medical debt, and employment disruption, which future studies should incorporate. Sarcoma subtype heterogeneity, spanning more than a dozen diagnoses from osteosarcoma to liposarcoma to gastrointestinal stromal tumor, precluded subtype specific analysis.

Even with those caveats, the implications are concrete. Because clinicians are often unprepared to counsel patients on financial hardship, and patients are often reluctant to raise the topic, routine screening for financial toxicity could open a conversation that currently rarely happens. The authors argue that identifying high risk individuals, including younger patients, women, racial minorities, those with metastatic disease, larger households, and those reporting anxiety, depression, pain, or sleep problems, should trigger access to financial navigation services and psychosocial support integrated into standard cancer care. Downstream, they suggest, such data could inform health policy on out of pocket costs at institutional, regional, and national levels, much as similar research has influenced prescription drug pricing debates. For a rare cancer community long overlooked in survivorship research, the study transforms an anecdote into an evidence base, and gives clinicians a quantifiable target for intervention.

Subject of Research: Prevalence and risk factors for financial toxicity among adult sarcoma patients during and after treatment

Article Title: Prevalence and Risk Factors for Financial Toxicity Among Sarcoma Patients During and Following Treatment Across the Lifespan

Article References: Robinson, M. J., Sun, L., Koyama, T., Schremp, E. A., Aronoff, G., Guimaraes, T., Stokes, T. A., Davis, E. J., Keedy, V., Borinstein, S. C., Schwartz, H. S., Halpern, J. L., Lawrenz, J. M., Johnson, D., Su, T., Luo, L., Osterman, T., Pal, T., Park, B. H., … Shinohara, E. T. (2026). Prevalence and Risk Factors for Financial Toxicity Among Sarcoma Patients During and Following Treatment Across the Lifespan. Cancer Reports, 9(10), Article e70686. https://doi.org/10.1002/cnr2.70686

Image Credits: AI Generated

DOI: 10.1002/cnr2.70686

Keywords: financial toxicity, sarcoma, COST measure, PROMIS-57, cancer survivorship, metastatic disease, health economics, patient-reported outcomes, Vanderbilt University Medical Center, CAUSAL cohort, psychosocial distress, cancer care costs